Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis

Allergen-specific immunotherapy has not been well-studied in the setting of increasingly common immune system-targeting medications. Subcutaneous immunotherapy may not be contraindicated in patients taking anti-CD20 mAbs antibodies and/or Janus kinase inhibitors.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of allergy and clinical immunology. Global 2025-05, Vol.4 (2), p.100411, Article 100411
Hauptverfasser: Sia, Twan, Bacchus, Leeon, Liu, Stanley, Leung, John
Format: Artikel
Sprache:eng
Schlagworte:
allergic rhinitis
B cell
CD20
JAK inhibitor
ofatumumab
SCIT
upadacitinib
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Allergen-specific immunotherapy has not been well-studied in the setting of increasingly common immune system-targeting medications. Subcutaneous immunotherapy may not be contraindicated in patients taking anti-CD20 mAbs antibodies and/or Janus kinase inhibitors.
ISSN:2772-8293
2772-8293
DOI:10.1016/j.jacig.2025.100411